GSK Archives -

The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults,

GSK continues campaign for greater adult immunisation coverage

https://pharmaphorum.com/views-and-analysis/gsk-continues-campaign-for-greater-adult-immunisation-coverage/

Vir awarded $1 billion multi-year BARDA influenza contract

Nicole Raleigh BARDA, COVID-19, GSK, influenza, pandemic, prevention, respiratory disease, SARS-CoV-2, sotrovimab, Vir Biotechnology, VIR-2482 0 Comment

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55

Vir awarded $1 billion multi-year BARDA influenza contract

https://pharmaphorum.com/news/vir-awarded-1-billion-multi-year-barda-influenza-contract/

Helping to support momentum on antimicrobial innovation

News/ News/ R&D

Undeterred by FDA setback, GSK snaps up Spero antibiotic

Phil Taylor antibiotic, antimicrobial resistance, fda, GSK, licensing, regulatory, Spero Therapeutics, tebipenem 0 Comment

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by

Undeterred by FDA setback, GSK snaps up Spero antibiotic

https://pharmaphorum.com/news/undeterred-by-fda-setback-gsk-snaps-up-spero-antibiotic/

R&D/ Views & Analysis/ Views and analysis

Preventing the next pandemic: Supporting early-stage R&D

Ben Hargreaves AstraZenca, COVID-19, GSK, pandemic, preventing the next pandemic 0 Comment

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various

Preventing the next pandemic: Supporting early-stage R&D

https://pharmaphorum.com/r-d/preventing-the-next-pandemic-supporting-early-stage-rd/

News/ News/ R&D

Relief for GSK as RSV vaccine clears phase 3 test in adults

Phil Taylor Bavarian Nordic, GSK, Johnson & Johnson, Moderna, Pfizer, respiratory syncytial virus, vaccine 0 Comment

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the

Relief for GSK as RSV vaccine clears phase 3 test in adults

https://pharmaphorum.com/news/relief-for-gsk-as-rsv-vaccine-clears-phase-3-test-in-adults/

Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Conducting successful commercial research in a primary care setting

Eloise McLennan clinical trials, GSK, Healum, NIHR, primary care 0 Comment

The primary care setting has garnered significant attention from industry stakeholders due to its promise in commercial research.

Conducting successful commercial research in a primary care setting

https://pharmaphorum.com/patients/conducting-successful-commercial-research-in-a-primary-care-setting/

News/ News/ Oncology

GSK’s ZEJULA gets green light for NHS use

Eloise McLennan GSK, NHS, NICE, ovarian cancer, regulatory approval 0 Comment

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some

GSK’s ZEJULA gets green light for NHS use

https://pharmaphorum.com/news/gsk-zejula-niraparib-gets-green-light-for-nhs-use/

R&D/ Views & Analysis/ Views and analysis

US vs EU: How can Europe translate home-grown innovation into biotech success?

Amanda Barrell BioNTech, Biotech, EU, GSK, Pfizer, Roche, The European Commission 0 Comment

We have seen a boom in biotech initial public offerings over the last two years, but many of

US vs EU: How can Europe translate home-grown innovation into biotech success?

https://pharmaphorum.com/r-d/us-vs-eu-translate-home-grown-innovation-into-biotech-success/

R&D/ Views & Analysis/ Views and analysis

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4

mike.hammerton@pharmaphorum.com Biogen, GSK, Merck, Q4 2021, quarterly results 0 Comment

While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4

https://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-pipeline-continues-to-provide-drama-as-investors-look-beyond-covid-in-q4/

Trending

GSK

Login